STOCK TITAN
  1. Home
  2. News
  3. TMDX

TransMedics to Present at the Cowen 41st Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ANDOVER, Mass., Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming Cowen 41st Annual Healthcare Conference. Management is scheduled to present on Wednesday, March 3, 2021 at 3:20 p.m. Eastern Standard Time.

Event: Cowen 41st Annual Healthcare Conference
Date: Wednesday, March 3, 2021
Time: 3:20 p.m. EST

A live and archived webcast of the presentation will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. 

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/transmedics-to-present-at-the-cowen-41st-annual-healthcare-conference-301229193.html

SOURCE TransMedics Group, Inc.

Stock TMDX logo
Transmedics Group Inc

NASDAQ:TMDX

TMDX Rankings

#1556 Ranked by Market Cap
#3404 Ranked by Stock Gains
N/A Ranked by Dividends

TMDX Latest News

Apr 16, 2024
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
Apr 8, 2024
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 19, 2024
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 28, 2024
TransMedics to Present at Upcoming March Investor Conferences
Feb 28, 2024
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TMDX Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Medical Specialties, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Andover

About TMDX

transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.